CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 6999 result(s)

2020 Virtual CADTH Symposium

Event Date: November 9, 2020 - November 10, 2020
Result type: Events

Connect with Canadian and international experts for two days of education, information sharing, and networking on the objective assessment and evaluation of health technologies.

Definition of Patient Group

Published on: October 29, 2020
Result type: General Content

For the purpose of Drug Reimbursement Reviews, a patient group is an organized group that represents patients with a specific disease or condition, or collection of diseases or conditions. Any interested patient group can provide input. We hear from small Facebook support groups and large national charities. A group should have members that are...

Patient Input and Feedback

Published on: October 29, 2020
Result type: General Content

CADTH seeks patients’ perspectives to improve the relevance and quality of our reviews. Also, to enable those possibly affected by the reviews to have an opportunity to contribute to them. For drug reimbursement reviews, CADTH invites patient groups to contribute input relevant to the drug it is reviewing. Steps for Providing Patient Input...

semaglutide (Rybelsus)

Last Updated: October 29, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: semaglutide
Indications: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes

  • Brand Name: Rybelsus
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0637-000
  • Project Status: Pending
  • Submission Type: Initial

CADTH Pharmaceutical Reviews Update — Issue 18

Last Updated: October 29, 2020
Result type: Reports
Product Line: Pharmaceutical Review Update

See Pharmaceutical Reviews Update – Issue 18 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:

  • updates on communications and web pages for CADTH drug reimbursement reviews
  • updates on clinician group input.

dupilumab (Dupixent)

Last Updated: October 29, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: dupilumab
Indications: Indicated in adults and adolescents 12 years and older as an add-on maintenance treatment for moderate-to-severe asthma characterized by type 2 inflammation. Indicated as maintenance therapy to improve lung function. Indicated as maintenance therapy for oral corticosteroid-dependent asthma irrespective of type 2 inflammatory markers.

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0667-000
  • Project Status: Pending
  • Submission Type: Initial

Open Calls for Patient and Clinician Input

Published on: October 29, 2020
Result type: General Content

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the Drug Reimbursement Review process. At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, revi...

COVID-19 Update

Published on: October 29, 2020
Result type: General Content

CADTH continues to support health care decision-makers throughout this challenging period. We have successfully shifted to a virtual office and have the tools in place to continue delivering our programs and services. Further, we continue to monitor our operations to identify potential disruptions to our core business activities and we will prom...